Christoph Roellig, MD, University Hospital Dresden, Dresden, Germany, discusses FLT3 ITD/NPM1 mutation status for patients with AML who are in first remission.
Christoph Röllig, MD, University Hospital Dresden, Dresden, Germany, discusses FLT3 ITD/NPM1 mutation status for patients with acute myeloid leukemia (AML) who are in first remission.
Röllig says that it is important to balance relapse risk, as well as risks associated with different consolidation treatments. There are two main options: chemo-consolidation with high dose cytarabine and alogeneic stem cell transplantation. He adds that alogeneic stem cell transplantation is associated with a higher treatment-related mortality and lower relapse rate. With chemo-consolidation, tolerability is better but the relapse rate is higher.
Röllig believes that we are learning more about minimal residual disease (MRD), which will enable physicians to taylor treatment to the level of response in MRD. He concludes that targeted therapies for patients with this mutation status will become available, such as tyrosine-kinase inhibitors (TKIs).
Cretostimogene Grenadenorepvec Shows High CR Rate in BCG-Unresponsive NMIBC
July 17th 2024Mark D. Tyson, II, MD, MPH, discussed treatment with cretostimogene grenadenorepvec in high-risk Bacillus Calmette-Guérin-unresponsive non-muscle invasive bladder cancer with carcinoma in situ and data from the BOND-003 trial.
Read More
Phase 3 VERIFY Trial Investigates Rusfertide’s Potential in Polycythemia Vera
July 16th 2024In an interview, Aniket Bankar, MD, discussed the background, design, and goals of the phase 3 VERIFY trial of the hepcidin mimetic rusfertide for the treatment of patients with polycythemia vera.
Read More
FDA Enforces Partial Hold on Trial of Seclidemstat in MDS/CMML
July 16th 2024Following the report of a serious and unexpected grade 4 adverse effect, a partial clinical hold has been placed on the phase 1 trial evaluating seclidemstat with azacitidine in myelodysplastic syndrome and chronic myelomonocytic leukemia.
Read More